Chairman's Statement
I am pleased to report an excellent performance by the Group during the period. We have achieved good growth in revenue and profitability from our UK businesses, increased market share at NVS, significantly increased US revenues, achieved further penetration of our products in Europe and launched new products in the UK. Furthermore, we have made an acquisition, VetXX Holdings A/S (“VetXX”), which materially increases our pharmaceutical portfolio and provides a strong European footprint to market the enlarged product range and future developed products . . .
Click here for Chairman's Statement
Business Review
Dechra Pharmaceuticals PLC (“Dechra”) operates under two Divisions, Pharmaceuticals and Services. The Pharmaceuticals Division operates internationally and is unique in having its sole area of specialisation in companion animal products. The Services Division serves UK veterinary practices in both the companion animal and livestock sectors. Following the acquisition of VetXX in January 2008 (which is detailed later in this review), the Group now employs 970 people and operates out of 11 countries . . .
Click here for Business Review